Every one of those 1 sits in a single category, market-trends. CSL Behring is most often covered alongside Grifols, which appears in 1 of these 1 story. Source depth averages 2 original sources per story, versus 6 across the same-window beat baseline.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about CSL Behring
Every one of those 1 sits in a single category, market-trends. CSL Behring is most often covered alongside Grifols, which appears in 1 of these 1 story. Source depth averages 2 original sources per story, versus 6 across the same-window beat baseline. At 6, the average consequence score sits above the same-window beat average of 5.8. CSL Behring appears in 1 tracked Healthcare story from February 20, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering CSL Behring. Shared-story counts are live from our verified record — not editorial picks.
The global immunoglobulin market is projected to reach $25.15 billion by 2031, fueled by a significant expansion in plasma collection infrastructure. This growth reflects rising clinical demand for antibody therapies and improved supply chain efficiencies across major pharmaceutical hubs.